Home A sensitive LC-MS/MS methotrexate assay capable of assessing adherence to methotrexate therapy in rheumatoid arthritis
Article
Licensed
Unlicensed Requires Authentication

A sensitive LC-MS/MS methotrexate assay capable of assessing adherence to methotrexate therapy in rheumatoid arthritis

  • Malcolm P. McTaggart ORCID logo EMAIL logo , James Bluett and Brian G. Keevil
Published/Copyright: August 4, 2023

Abstract

Objectives

To develop a sensitive liquid chromatography-tandem mass spectrometry method capable of measuring serum methotrexate in patients with rheumatoid arthritis to assess adherence to drug treatment.

Methods

Isotopically labelled internal standard and deionised water were added to sample prior to solid phase extraction using a Waters Oasis Max ion-exchange 96-well plate. Following extraction, samples were analysed by LC-MS/MS on a TQS-micro mass spectrometer.

Results

Mean recovery was 107 % for four different concentrations of methotrexate spiked into seven patient samples, whilst post extraction spiking gave a mean recovery of 100 %. Between-batch and within-batch CVs were ≤6 % at three different concentrations of methotrexate in fresh frozen plasma. Mean bias was <5 % for between-batch and within batch analysis at three different weighed in concentrations of methotrexate certified reference material. The lower limit of quantification of the assay was 0.1 nmol/L with linearity up to approximately 100 nmol/L. Dilution linearity studies were used to validate the dilution of patient samples prior to analysis. There was no significant interference in the method from lipaemia, haemolysis or icterus.

Conclusions

A sensitive LC-MS/MS assay for methotrexate has been developed and validated. The method has been used to measure methotrexate adherence in patient samples from clinical trials and could be used in future research to assess the ability of the assay as a biofeedback intervention to improve adherence to methotrexate therapy.


Corresponding author: Malcolm P. McTaggart, Department of Clinical Biochemistry, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust, Southmoor Road, Manchester, M23 9LT, UK, E-mail:

Funding source: The MIRA study is funded by The Association of Physicians of Great Britain & Ireland and supported by Versus Arthritis (21754) and the NIHR Manchester Biomedical Research Centre (NIHR203308). N/A

Award Identifier / Grant number: N/A

Acknowledgments

We thank laboratory staff in biochemistry at Wythenshawe Hospital for providing a productive working environment allowing this work to be carried out. Additionally we thank UKNEQAS for providing samples free of charge.

  1. Research funding: The MIRA study is funded by The Association of Physicians of Great Britain & Ireland and supported by Versus Arthritis (21754) and the NIHR Manchester Biomedical Research Centre (NIHR203308).

  2. Author contributions: Professor Brian Keevil developed the method. Dr Malcolm McTaggart performed the other laboratory work including method validation and clinical trial work. Dr Malcolm Mctaggart produced the first draft of the manuscript. Dr James Bluett provided the clinical trial samples. All authors edited the manuscript and contributed to the final version.

  3. Competing interests: No conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in the MIRA study.

  5. Ethical approval: Ethical approval for MIRA was given by the North West – Haydock Research Ethics Committee (19/NW/0047) and all participants provided written informed consent. The method validation did not require ethical approval.

References

1. Smolen, JS, Landewe, RB, Bijlsma, JW, Burmester, GR, Dougados, M, Kerschbaumer, A, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. https://doi.org/10.1136/annrheumdis-2019-216655.Search in Google Scholar PubMed

2. National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. NG100; 2018. https://www.nice.org.uk/guidance/ng100/resources/rheumatoid-arthritis-in-adults-management-pdf-66141531233989 [Accessed 1 Feb 2023].Search in Google Scholar

3. Bluett, J, Riba-Garcia, I, Verstappen, SM, Wendling, T, Ogungbenro, Unwin, RD, et al.. Development and validation of a methotrexate adherence assay. Ann Rheum Dis 2019;78:1192–7. https://doi.org/10.1136/annrheumdis-2019-215446.Search in Google Scholar PubMed PubMed Central

4. Barton, A, Jani, M, Bundy, C, Bluett, J, McDonald, S, Keevil, B, et al.. Translating research into clinical practice: quality improvement to halve non-adherance to methotrexate. Rheumatology 2020;60:125–31. https://doi.org/10.1093/rheumatology/keaa214.10.1093/rheumatology/keaa214Search in Google Scholar PubMed PubMed Central

5. Food and Drug Administration, Department of Health and Health Services. Guidance for industry. Bioanalytical method evaluation. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf [Accessed 7 Jul 2023].Search in Google Scholar

6. McTaggart, MP, Keevil, BG. A rapid LC-MS/MS assay for the measurement of serum methotrexate in patients who have received high doses for chemotherapy. Ann Clin Biochem 2021;58:599–604. https://doi.org/10.1177/00045632211031284.Search in Google Scholar PubMed

7. ClinicalTrials.gov. Methotrexate use improvement in rheumatoid arthritis using biomarker feedback. https://clinicaltrials.gov/ct2/show/NCT03913728 [Accessed 7 Jul 2023].Search in Google Scholar

8. Bluett, J, Hyrich, KL, Keevil, B, Doran, P, Barton, A. Feasibility study of methotrexate use improvement in rheumatoid arthritis using biomarker feedback. Rheumatology 2023;62(2 Suppl):P106.10.1093/rheumatology/kead104.147Search in Google Scholar

9. Engel, A, Ruhe, L, Singh, N, Wright, JA, Liesch, F, Bauland, F, et al.. An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of methotrexate in human serum and plasma. Clin Chem Lab Med 2023;61:1917–29. https://doi.org/10.1515/cclm-2022-1001.Search in Google Scholar PubMed


Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/cclm-2023-0350).


Received: 2023-04-05
Accepted: 2023-07-07
Published Online: 2023-08-04
Published in Print: 2024-01-26

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Biological management of diabetes mellitus, the laboratory medicine specialist and the patient
  4. Reviews
  5. Remote HbA1c testing via microsampling: fit for purpose?
  6. The effect of hormonal contraceptive therapy on clinical laboratory parameters: a literature review
  7. Opinion Paper
  8. Continuous glucose monitoring has an increasing role in pre-symptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing
  9. IFCC Paper
  10. Comparison and commutability study among four faecal immunochemical tests (FIT) systems
  11. Guidelines and Recommendations
  12. Evidence-based procedures to improve the reliability of circulating miRNA biomarker assays
  13. General Clinical Chemistry and Laboratory Medicine
  14. Commutability assessment of candidate reference materials for plasma renin activity measurement: current challenges
  15. Aggregated data from the same laboratories participating in two glucose external quality assessment schemes show that commutability and transfers of values to control materials are decisive for the biases found
  16. Methodological considerations in determining sex steroids in children: comparison of conventional immunoassays with liquid chromatography-tandem mass spectrometry
  17. From “wet” matrices to “dry” blood spot sampling strategy: a versatile LC-MS/MS assay for simultaneous monitoring caffeine and its three primary metabolites in preterm infants
  18. A sensitive LC-MS/MS methotrexate assay capable of assessing adherence to methotrexate therapy in rheumatoid arthritis
  19. Determination of cortisone and cortisol in human scalp hair using an improved LC-MS/MS-based method
  20. Mild hypophosphatasia may be twice as prevalent as previously estimated: an effective clinical algorithm to detect undiagnosed cases
  21. Combined deficient response to polysaccharide-based and protein-based vaccines predicts a severe clinical phenotype
  22. Reference Values and Biological Variations
  23. A sex-specific association of leukocyte telomere length with thigh muscle mass
  24. Cancer Diagnostics
  25. Optimized procedure for high-throughput transcriptome profiling of small extracellular vesicles isolated from low volume serum samples
  26. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics
  27. Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer
  28. Development and analytical validation of a novel nasopharynx swab-based Epstein-Barr virus C promoter methylation quantitative assay for nasopharyngeal carcinoma detection
  29. Infectious Diseases
  30. (Pre)analytical considerations concerning the analysis of synovial calprotectin
  31. Corrigendum
  32. Thermal and chronological stability of monocyte distribution width (MDW), the new biomarker for sepsis
  33. Acknowledgment
  34. Acknowledgment
  35. Letters to the Editor
  36. In-house diagnostic devices under the EU IVDR and unwanted side-effects of intentional transparency
  37. Use of thyroid function tests in urine: a position statement of the Belgian Thyroid Club
  38. State of the art of measurement uncertainty of serum ferritin
  39. Analytical performance evaluation and consumable waste reduction strategies using a tube-based quality control material
  40. Stability of fecal calprotectin extracts using the Diasorin® kit
  41. Reverse cascade testing from newborn screening: the opportunity to improve family healthcare outcomes
  42. An indirect data-mining approach to standardise paediatric serum phosphate reference intervals in Wales
  43. Sodium and risk assessment of osmotic demyelination syndrome: the method matters!
Downloaded on 23.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2023-0350/html
Scroll to top button